Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mobocertinib: Mechanism of action, clinical, and translational science.

Clinical and translational science - 1 Mar 2024

Hanley Michael J, Camidge D Ross, Fram Robert J, Gupta Neeraj

Abstract excerpt

Epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations represent ~6%-12% of all EGFR-mutated non-small cell lung cancer (NSCLC) cases. First-, second-, and third-generation tyrosine kinase inhibitors (TKIs) have limited clinical activity against EGFR ex20ins mutations. Mobocertinib is a first-in-class oral EGFR TKI that selectively targets in-frame EGFR ex20ins mutations in NSCLC;...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indoles

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 38511563
DOI: 10.1111/cts.13766
PMCID: PMC10955621

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mobocertinib: Mechanism of action, clinical, and translational science.PMID 38511563Read ↗

First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer in the Phase III EXCLAIM-2 TrialSemantic proximity Read ↗

Mobocertinib in non-small cell lung cancer.Semantic proximity Read ↗

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy AnalysisSemantic proximity Read ↗

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 InsertionsSemantic proximity Read ↗

A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.Semantic proximity Read ↗

Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations.Semantic proximity Read ↗

A study of high dose furmonertinib in EGFR exon 20 insertion mutation-positive advanced non-small cell lung cancerSemantic proximity Read ↗

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabSemantic proximity Read ↗

Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion MutationsSemantic proximity Read ↗

Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.